Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon A Mahal

Showing results (121-130 of 214) with videos related to

Pageof 22
Sort By:
Brachytherapy|April 19, 2015
Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancerVinayak Muralidhar, Brandon A Mahal, David R Ziehr, et al.
BJU International|July 25, 2015
Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?Brandon A Mahal, Vinayak Muralidhar, Yu-Wei Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2019
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen LevelVinayak Muralidhar, Paul L Nguyen, Brandon A Mahal, et al.
JCO Oncology Practice|January 22, 2024
Disparities in Stage at Presentation Among Hispanic and Latinx Patients With Non-Small-Cell Lung Cancer in the United StatesEdward Christopher Dee, Nishwant Swami, Bahaa Kazzi, et al.
Urology|August 9, 2020
Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-makingNayan Lamba, Santino Butler, Brandon A Mahal, et al.
Cancer|March 13, 2016
National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base studyBrandon A Mahal, Yu-Wei Chen, Jason A Efstathiou, et al.
Cancer|December 4, 2019
Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012Santino S Butler, Vinayak Muralidhar, Shuang G Zhao, et al.
Urology|April 15, 2021
Clinical characterization of radiation-associated muscle-invasive bladder cancerSybil T Sha, Edward Christopher Dee, Matthew Mossanen, et al.
The Prostate|February 23, 2026
Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker InvestigationAlireza Abdshah, Mohammad Alyamani, Robert A Burgess, et al.
Prostate Cancer and Prostatic Diseases|March 20, 2022
Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic menNishwant Swami, Yefri A Baez, Idalid Franco, et al.
Pageof 22

Showing results (121-130 of 214) with videos related to

Sort By:
Pageof 22
Brachytherapy|April 19, 2015
Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancerVinayak Muralidhar, Brandon A Mahal, David R Ziehr, et al.
BJU International|July 25, 2015
Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?Brandon A Mahal, Vinayak Muralidhar, Yu-Wei Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 8, 2019
Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen LevelVinayak Muralidhar, Paul L Nguyen, Brandon A Mahal, et al.
JCO Oncology Practice|January 22, 2024
Disparities in Stage at Presentation Among Hispanic and Latinx Patients With Non-Small-Cell Lung Cancer in the United StatesEdward Christopher Dee, Nishwant Swami, Bahaa Kazzi, et al.
Urology|August 9, 2020
Three-tiered Subclassification System of High-risk Prostate Cancer in Men Managed With Radical Prostatectomy: Implications for Treatment Decision-makingNayan Lamba, Santino Butler, Brandon A Mahal, et al.
Cancer|March 13, 2016
National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base studyBrandon A Mahal, Yu-Wei Chen, Jason A Efstathiou, et al.
Cancer|December 4, 2019
Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012Santino S Butler, Vinayak Muralidhar, Shuang G Zhao, et al.
Urology|April 15, 2021
Clinical characterization of radiation-associated muscle-invasive bladder cancerSybil T Sha, Edward Christopher Dee, Matthew Mossanen, et al.
The Prostate|February 23, 2026
Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker InvestigationAlireza Abdshah, Mohammad Alyamani, Robert A Burgess, et al.
Prostate Cancer and Prostatic Diseases|March 20, 2022
Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic menNishwant Swami, Yefri A Baez, Idalid Franco, et al.
Pageof 22